Effects of Opioid Withdrawal on Psychobiology in People Living with HIV.

HIV Russia opioid withdrawal

Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
06 Jan 2024
Historique:
received: 23 10 2023
revised: 20 12 2023
accepted: 21 12 2023
medline: 23 1 2024
pubmed: 23 1 2024
entrez: 23 1 2024
Statut: epublish

Résumé

Many persons with opioid use disorders (OUDs) have HIV disease and experience clinically significant stress after they enroll in abstinence-based treatment and undergo medically assisted withdrawal. We examined whether opioid withdrawal affects virologic control, inflammatory markers, cognition, and mood in persons with an OUD and HIV, and explored whether measures of withdrawal stress, such as activation of the HPA axis, contribute to alterations in immune function, cognition, and mood. Study participants were 53 persons with HIV who were admitted for OUD treatment at the City Addiction Hospital in Saint Petersburg, Russian Federation. Participants were examined at admission, at the anticipated peak of withdrawal 3 to 7 days after the last day of a clonidine-based withdrawal process lasting 7 to 14 days, and 3 to 4 weeks after completing withdrawal. At these times, participants received medical exams and were evaluated for symptoms of withdrawal, as well as cognition and mood. Viral load, plasma cortisol, DHEA sulfate ester (DHEA-S), interleukin-6 (IL-6), and soluble CD14 (sCD14) were determined. Multivariable models examined the relationships between markers of HPA activation and the other parameters over time. HPA activation as indexed by cortisol/DHEA-S ratio increased during withdrawal, as did markers of immune activation, IL-6 and sCD14. There were no significant associations between viral load and indicators of HPA activation. In longitudinal analyses, higher cortisol/DHEA sulfate was related to worse cognition overall, and more mood disturbance. Increase in IL-6 was associated with worse cognitive performance on a learning task. There were no significant associations with sCD14. Worsening of cognition and measures of mood disturbance during withdrawal were associated with activation of the HPA axis and some measures of inflammation. Whether repeated episodes of opioid withdrawal have a cumulative impact on long-term HIV outcomes and neurocognition is a topic for further investigation.

Identifiants

pubmed: 38257791
pii: v16010092
doi: 10.3390/v16010092
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAAA NIH HHS
ID : R21 DA036607
Pays : United States

Auteurs

Igor Grant (I)

HIV Neurobehavioral Research Program, Department of Psychiatry, University of California San Diego, San Diego, CA 92103, USA.

Evgeny Krupitsky (E)

Department of Pharmacology, Pavlov State Medical University, 197022 Saint Petersburg, Russia.
Department of Addictions, Bekhterev National Medical Research Center for Psychiatry and Neurology, 192019 Saint Petersburg, Russia.

Marina Vetrova (M)

Department of Pharmacology, Pavlov State Medical University, 197022 Saint Petersburg, Russia.

Anya Umlauf (A)

HIV Neurobehavioral Research Program, Department of Psychiatry, University of California San Diego, San Diego, CA 92103, USA.

Robert K Heaton (RK)

HIV Neurobehavioral Research Program, Department of Psychiatry, University of California San Diego, San Diego, CA 92103, USA.

Richard L Hauger (RL)

HIV Neurobehavioral Research Program, Department of Psychiatry, University of California San Diego, San Diego, CA 92103, USA.
Center for Behavior Genetics of Aging, University of California San Diego, La Jolla, CA 92093, USA.
Center of Excellence for Stress and Mental Health, VA San Diego Healthcare System, San Diego, CA 92093, USA.

Olga Toussova (O)

Department of Pharmacology, Pavlov State Medical University, 197022 Saint Petersburg, Russia.

Donald R Franklin (DR)

HIV Neurobehavioral Research Program, Department of Psychiatry, University of California San Diego, San Diego, CA 92103, USA.

Scott L Letendre (SL)

HIV Neurobehavioral Research Program, Department of Psychiatry, University of California San Diego, San Diego, CA 92103, USA.
Department of Medicine, University of California, San Diego, CA 92093, USA.

George Woody (G)

Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA.

Elena Blokhina (E)

Department of Pharmacology, Pavlov State Medical University, 197022 Saint Petersburg, Russia.

Dmitry Lioznov (D)

Department of Pharmacology, Pavlov State Medical University, 197022 Saint Petersburg, Russia.

Edwin Zvartau (E)

Department of Pharmacology, Pavlov State Medical University, 197022 Saint Petersburg, Russia.

Classifications MeSH